NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr Ruben Herrendorff as its new CEO to drive the next stage of its development.The Company also announced that it has appointed Dr Ulf Grawunder to its Board of Directors.
NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland and is committed to creating tomorrow’s safe immunotherapies by leveraging a novel targeted approach in T cell immunology.
“NXI Therapeutics aims to develop modulators of the coronin 1 signaling pathway as a novel class(es) of drugs which have the potential to bring about significant and meaningful clinical improvements for people affected by autoimmune disorders and/or following transplantation. We have recently bolstered our strong scientific expertise with biopharmaceutical entrepreneurial experience, and are now well placed for the next exciting growth stage. Ruben significantly strengthens the management and will help to bring our important medicines to clinical validation,” says Rajesh Jayachandran, co-founder and CSO of NXI Therapeutics.
